MRK

Merck & Co., Inc.

$148.05

-0.48%
SectorHealthcareIndustryDrug Manufacturers - GeneralCountryUnited States

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands.

Source: Yahoo Finance
AI summary

Price & performance

1M+5.3%
3M+15.2%
YTD+40.9%
1Y+79.2%
52-week range—
Beta0.29
Full chart and returns against a benchmark

Q-Score

53/ 100

Quality against peers; 50 is the peer median.

Growth53
Risk69
Performance57
Valuation48
Profitability54
Leverage40
Sentiment41
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$65B+1.3%
Net income$18.3B+6.6%
Net margin28.1%+1.4 pts
Historical fundamentals

Revenue exposure

44%of revenue from outside the US
United States56%
Non-US44%
Regions, segments, customers and suppliers

Valuation

MRKIndustryP/E148.7938.98P/S5.426.74EV/EBITDA—40.57P/B8.1310.26PEG——
Dividend yield2.29%
Every valuation metric

Earnings

Oct 29next report, before the open
EPS estimate$2.10
Beats (last 4 quarters)—
Average surprise—
EPS revisions (30d)—
Every quarter against its estimate